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Abstract
Nevoid basal cell carcinoma syndrome (NBCCS), also known as Gorlin syndrome, is a hereditary
condition characterized by a wide range of developmental abnormalities and a predisposition to
neoplasms.
The estimated prevalence varies from 1/57,000 to 1/256,000, with a male-to-female ratio of 1:1.
Main clinical manifestations include multiple basal cell carcinomas (BCCs), odontogenic keratocysts
of the jaws, hyperkeratosis of palms and soles, skeletal abnormalities, intracranial ectopic
calcifications, and facial dysmorphism (macrocephaly, cleft lip/palate and severe eye anomalies).
Intellectual deficit is present in up to 5% of cases. BCCs (varying clinically from flesh-colored
papules to ulcerating plaques and in diameter from 1 to 10 mm) are most commonly located on
the face, back and chest. The number of BBCs varies from a few to several thousand. Recurrent
jaw cysts occur in 90% of patients. Skeletal abnormalities (affecting the shape of the ribs, vertebral
column bones, and the skull) are frequent. Ocular, genitourinary and cardiovascular disorders may
occur. About 5–10% of NBCCS patients develop the brain malignancy medulloblastoma, which may
be a potential cause of early death.
NBCCS is caused by mutations in the PTCH1 gene and is transmitted as an autosomal dominant
trait with complete penetrance and variable expressivity.
Clinical diagnosis relies on specific criteria. Gene mutation analysis confirms the diagnosis. Genetic
counseling is mandatory. Antenatal diagnosis is feasible by means of ultrasound scans and analysis
of DNA extracted from fetal cells (obtained by amniocentesis or chorionic villus sampling). Main
differential diagnoses include Bazex syndrome, trichoepithelioma papulosum multiplex and Torre's
syndrome (Muir-Torre's syndrome).
Management requires a multidisciplinary approach. Keratocysts are treated by surgical removal.
Surgery for BBCs is indicated when the number of lesions is limited; other treatments include laser
ablation, photodynamic therapy and topical chemotherapy. Radiotherapy should be avoided.
Vitamin A analogs may play a preventive role against development of new BCCs.
Life expectancy in NBCCS is not significantly altered but morbidity from complications can be
substantial. Regular follow-up by a multi-specialist team (dermatologist, neurologist and
odontologist) should be offered. Patients with NBCCS should strictly avoid an excessive sun
exposure.
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Disease name and synonyms
Nevoid basal cell carcinoma syndrome (NBCCS)
Gorlin syndrome
Gorlin-Goltz syndrome
Basal cell nevus syndrome, BCNS (OMIM 109400)
Fifth phacomatosis
Definition
The syndrome, delineated by Gorlin and Goltz in 1960
[1], was first reported in 1894 [2,3] and has been given
several different names:
￿ Gorlin syndrome
￿ Gorlin-Goltz syndrome
￿ Nevoid basal cell carcinoma syndrome (NBCCS)
￿ Multiple nevoid basal-cell carcinoma syndrome
(MNBCCS)
￿ Multiple basal-cell carcinoma syndrome
￿ Basal cell nevus syndrome (BCNS)
￿ Multiple basalioma syndrome
￿ Fifth phacomatosis
￿ Jaw cysts-basal cell tumors-skeletal anomalies syndrome
￿ Odontogenic keratocytosis-skeletal anomalies syn-
drome
￿ Multiple nevoid basal-cell epithelioma-jaw cysts-bifid
rib syndrome
￿ Hereditary cutaneomandibular polyoncosis
￿ Epitheliomatose multiple generalisee
Currently, this disorder, resulting from mutations in the
PTCH1 gene, is called the nevoid basal cell carcinoma syn-
drome (NBCCS), as Professor Gorlin suggested. However,
patients and their relatives prefer to use the name "Gorlin
syndrome", since it does not contain the word "carci-
noma", even if about 50% of white patients will develop
a significant number of skin cancers. Skin cancers do not
generally occur in black patients [4].
Diagnostic criteria, based on the most frequent and/or
specific features of the syndrome, were defined by Evans
et al. in the Journal of Medical Genetics in 1993 [5], and
modified by Kimonis et al. in 1997 [6].
Epidemiology
This syndrome existed during Dynastic Egyptian times as
shown by a constellation of findings compatible with the
syndrome in mummies dating back to 1,000 b.c. [7]. In
1992, Farndon et al. estimated that the minimum preva-
lence is 1 per 57,000 [8,9]. An almost identical value was
noted by Pratt and Jackson [10]. A study in the North West
of England showed that the disease affects 1 in 55,600
people [5]. In Italy, the incidence (1/256,000) [11] of the
disease appears to be lower than in Australia (1/164,000)
[12] and in the United Kingdom [5] (Table 1). Rahbari
and Mehregan noted that 2% of patients under 45 years of
age with basal cell carcinomas have the syndrome [13].
Recently two new studies reported the incidence of the
syndrome in Korea [14], and in France[15].
Clinical description
Many different signs and symptoms may be associated
with NBCCS (Table 2). Clinical manifestations include
basal cell carcinomas (BCCs), which may appear very
early (2 years of age) [16]; odontogenic keratocysts
(OKCs) that generally develop in the first, second and
third decades [6,11,12,17,18]; palmar and/or plantar pits,
and ectopic calcifications of the falx cerebri. These mani-
festations are considered as the major criteria for diagno-
sis [5]. The disorder is also characterized by congenital
skeletal abnormalities, macrocephaly with frontal boss-
ing, cleft lip and/or palate, and eye anomalies. Various
low-frequency neoplasms, such as medulloblastomas,
meningiomas, and ovarian and cardiac fibromas have
been also reported (Table 2).
Skin
Basal cell carcinomas may arise in various stages of the syn-
drome: most often they appear between puberty and 35
years of age [16], but cases have been reported in 3 or 4
year-old patients [5,12]; in general, the mean age of onset
is about 25 years of age. The incidence varies widely
among ethnic groups: only about 40% of black patients
affected by NBCCS manifest BCCs, while in whites they
are reported in up to 90% of cases. However, the inci-
dence in whites is also variable with some studies showing
a lower prevalence (30%), probably due to protective skin
pigmentation [11], as already established for African-
American patients [6,19]. BCCs may vary in number
(from a few to literally thousands) and range in size from
1 to 10 mm in diameter. Clinically, they may vary from
flesh-colored papules to ulcerating plaques and may be
mistaken for skin tags, nevi, or hemangiomas. There
appears to be a relationship with increased sun exposure,Orphanet Journal of Rare Diseases 2008, 3:32 http://www.ojrd.com/content/3/1/32
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and therefore BCCs are most likely to appear on the sun-
exposed parts of the body, but non-exposed areas may
also be involved. The most common locations are the
face, the back, and the chest; the waist and extremities are
rarely involved; BCCs have also been described on genita-
lia [20]. BCCs in this syndrome behave in the same man-
ner as sporadic BCCs. In general, it is after puberty that the
basal cell cancers become aggressive and invade locally
[5]. If a lesion increases in size or begins to bleed or crust,
invasion should be suspected and excluded. Radiation
therapy must be avoided [6,21], since tumors may appear
in the radiation fields even after many years [16]. Evi-
dence of metastatization has been rarely reported [22,23].
If left untreated, BCCs can lead to disfigurment, especially
on the face. Wang and Goldberg reported a patient with
NBCCS who developed multiple polypoid basal cell carcino-
mas (PBCC) in the perineum, leading to the recommenda-
tion that the perineum, perianal, and genital areas should
be included in the routine examination of patients with
NBCCS [24]. The histopathology of nevoid BCC cannot
be differentiated from that of ordinary sporadic BCC [4].
The tumors are composed of nests and islands or sheets of
large, deeply-stained nuclei with indistinct cell mem-
branes [4]. At the periphery of each lesion, the epithelial
cells are well-polarized, suggestive of cutaneous basal
cells. About 30% of NBCCS patients have two or more
types of BCC patterns (morphea-like, solid, superficial,
cystic, adenoid, fibroepithelial) [4]. Commonly (30–50%
of cases), there are milia intermixed with the basal cell
islands and calcified foci may be noted, not only within
the tumor but also in normal skin [4]. Perhaps this reflects
the "turning on" of the bone morphogenetic protein
(BMP) gene [4].
Between 30% and 65% of patients with the syndrome
have small asymmetric palmar-plantar pits by the age of 10
years, this percentage rising to 80% by the age of 15
[21,25]. Pits occur in 85% of patients over the age of 20
years [25]. These lesions are 2–3 mm in diameter and 1–
3 mm in depth [26], with the color of the base being red
in caucasians and black in africans. They increase in
number with age, are permanent, and are a strong diag-
nostic indicator whenever found in a child. They are
found more commonly on the palms (77%) than on the
soles (50%). The pits may be easier to see if the hands are
soaked in warm water for about 10 minutes. No BCC has
been found to arise from these pits [21].
Multiple nevi are present in 30–50% of patients under 20
years of age, rising to 70% in patients over the age of 20
years. The nevi are flesh colored, reddish brown or pearly,
and the groups resemble moles, skin tags, an ordinary
nevus, cell nevi or hemangiomas. Some of them grow rap-
idly for a few days (to a few weeks), then mostly remain
static.
Other skin signs are nodular or patch lesions, and benign der-
mal cysts. Small keratin-filled cysts (milia) can be found on
the face in 30% of cases, most commonly in the area
below the eyes, but they can also occur on the forehead.
Epidermoid cysts occur on the limbs and the trunk in over
50% of cases. They are usually 1–2 cm in diameter and are
particularly common around the knee. Skin tags are espe-
cially common around the neck; histopathology reveals
the typical features of a basal cell carcinoma, but the skin
tags do not generally change in size or shape.
Table 1: Comparison of prevalence and frequency of major criteria in NBCCS patients among four studies.
Evans et al. [5] 
United Kingdom, 
1993
Shanley et al. [12] 
Australia, 1994
Kimonis et al. [6] 
United States, 
1997
Lo Muzio et al. 
[11] Italy, 1999
Ahn SG et al. [14] 
Korea, 2004
Pruvost-Balland et 
al. [15] France, 
2006
Patients 84 118 105 37 33 22
Prevalence 1/56,000 1/164,000 NR 1/256,000 1/13,939,393 NR
Major criteria % or (% African-Americans)
BCCs 47 76 80 (38) 30 15.2 100
A g e  >  2 0  y 7 38 59 11 7- -
A g e  >  4 0  y 9 09 59 77 5- -
J a w  c y s t 6 67 57 49 29 0 . 9 6 2
Palm/plant pits 71 80 87 35 66.7 45
Calcification of falx 
cerebri
NR 92 65 70 21.2 66
NBCCS = Nevoid basal cell carcinoma syndrome; NR-Non reportedOrphanet Journal of Rare Diseases 2008, 3:32 http://www.ojrd.com/content/3/1/32
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Table 2: Disorders reported in patients with basal cell nevus syndrome.
Clinical manifestations
Skin Central nervous system
Cutaneous dyskeratosis: Ectopic calcification:
 erythematous-squamous spots degenerating in NBCC  falx cerebri
 tentorium cerebelli
 nodular or patch lesions  spotted meningeal calcification
 palmo-plantar pits  complete or partial bony bridging of the sella turcica
Multiple basal cell carcinomas
Benign dermal cysts Meningioma
 Multiple nevi Medulloblastoma
Multiform glioblastoma
Moderate mental retardation
Grand mal
Congenital hydrocephalus
Huntington's chorea
Stomatologic system Ocular system
Odontogenic keratocysts Cataract, coloboma, microphthalmia
Dental ectopy, heterotopy Chalazions
Impacted teeth Internal strabismus
Dental agenesis Rotatory nistagmus
Malocclusion Exophthalmus
Maxillary fibrosarcoma Hypertelorism
Ameloblastoma Congenital blindness
Odontogenic myxoma
Spindle cell carcinoma
Cleft palate and lip
Mandibular prognathism
High-arched palate
Squamous cell carcinoma
Skeletal open bite
Idiopathic pseudocyst
Hyperplasia of the mandibular coronoid processes
Musculo-skeletal system Cardio-vascular system
Congenital skeletal anomalies: Cardiac fibroma (interventricular septum)
 bifid, fused, splayed, or missing ribs Absent internal carotid artery
 bifid wedges fused vertebra
 scoliosis
 frontal, temporal and parietal bossing
 polydactyly
 sindactyly
 short fourth metarcapal
 sprengel shoulder
Polyostotic bone cysts
Genito-urinary system Auditory system
Males: Middle ear anomalies
 hypogonadism  otosclerosis
 cryptorchidism  conductive hearing loss
Females: Posteriorly angulated ears
 ovarian calcifications
 ovarian cysts
 ovarian fibroma
hypogonadism
Respiratory system Biochemical findings
Bronchogenic cysts High levels of CAMP
Hyaline membrane disease High levels of AP
Gastro-enteric system
Linfomesenteryc cysts
Gastric polypsOrphanet Journal of Rare Diseases 2008, 3:32 http://www.ojrd.com/content/3/1/32
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Recently, Wilson et al. reported the occurrence of hairy skin
patches  (discrete patches of unusually long pigmented
hair) on the skin of three patients affected by Gorlin syn-
drome from two unrelated families with confirmed heter-
ozygous mutations in the PTCH1 gene, suggesting that the
patches may represent a sign associated with the syn-
drome [27].
Stomatologic system
Recurrent jaw cysts are the main oral sign, being present
in 90% of patients [11]. These cysts are known as kerato-
cysts as they are characterized by a thin external fibrous
capsule and an internal lining of keratinized stratified
squamous epithelium. Keratocysts appear in the tooth-
bearing areas of the jaws, and are believed to arise from
the dental lamina [21]. Cysts may appear in both jaws. In
several cases, the first symptom is either an odontogenic
keratocyst or an odontogenic cyst of the jaws [11,18].
Odontogenic keratocysts (OKCs) are the most consistent
and representative signs of NBCCS in the first and the sec-
ond decades of life. OKCs are detected in patients under
10 years of age [5,12]: 13% of patients develop a jaw cyst
by the age of 10 years and 51% by the age of 20 years.
These data suggest that lesions may start to develop as
early as at 7 or 8 years of age and underline the fact that
keratocysts in patients affected by NBCCS arise earlier
than those in healthy subjects [28,29]. In NBCC patients,
there is continued development of new and recurring cysts
until about age 30, when the rate of development tends to
decrease [30]. Most non-NBCCS keratocysts are isolated
lesions, but in NBCCS the keratocysts are commonly mul-
tiple, from 1 to 30, and the average number is 5. The most
common site in the mandible is the molar-ramus region
(44%), followed by the incisor-canine region (18%) [18].
In contrast, the majority of maxillary cysts occur in the
incisor-canine (15%) and molar-tuberosity (13%) regions
[18]. Only a few cysts have been reported in the premolar
region. There is no racial predilection. There may be
remarkably few symptoms until cysts reach a large size,
especially when the ascending ramus is involved. Presen-
tations include swelling and/or displaced, impacted teeth.
About one-half of patients present with swelling, a quarter
with mild pain, and 15% with an unusual taste following
rupture of a cyst. Despite these manifestations, jaw frac-
tures almost never occur. Radiographically, the keratocyst
may show a unilocular or multilocular pattern and the
cystic spaces may have a smooth or scalloped border. One
of the most problematic aspects is the 60% rate of recur-
rence following surgery. In part, this may be due to incom-
plete removal, i.e., from retention of epithelial islands
and/or satellite microcysts, which occur with great fre-
quency in the connective tissue capsule, or from prolifer-
ation of the basal layer of the epithelium [31]. There have
been a few reports of ameloblastoma arising in odon-
togenic keratocysts [32] or, rarely, of squamous cell carci-
noma [33]. Microscopically, the odontogenic keratocysts
are multilocular with a parakeratinized (96%) or, rarely,
orthokeratinized (4%) stratified squamous epithelium
consisting of only a few layers of cells (about five to eight)
with a well-defined basal epithelial cell layer, palisaded
nuclei but no rete ridges [4]. Budding of the epithelium
into the connective tissue with suprabasilar splitting has
been noted in at least 50% of cases [4].
Other defects of the stomatologic system are malocclu-
sion, impacted teeth, mandibular prognathism, dental
ectopy or heterotopy, and dental agenesis. Cleft palate
and lip are rare (5%) [34,35]. Recently, a new sign has
been described: bilateral hyperplasia of the mandibular
coronoid processes [36], which may be a radiologic crite-
rion for the syndrome, useful for establishing a diagnosis
especially in pediatric patients [37].
Ectopic calcification of the central nervous system and 
other brain signs
Ectopic calcifications of the central nervous system have
been reported: lamellar calcification of the falx cerebri (70–
85%) [11], calcification of the tentorium cerebelli (20–40%)
[11], the petroclinoid ligament (20%) and the diaphragma
sellae (60–80%) [38], and complete or partial bony bridging
of the sella turcica (25%) [11]. Spotted meningeal calcifica-
tions are rare. These signs may not result in clinical mani-
festations, but can be useful in confirming the diagnosis.
The calcification of the falx cerebri can appear very early in
life, and is often strikingly apparent from late childhood.
Other signs reported are cysts of the choroid plexus of the
third and lateral ventricles of the brain, intraparenchymal
brain cysts, arachnoid cysts, glial nodules projecting from
the lateral ventricles, agenesis of the corpus callosum with
or without lipoma [39], "empty" sella syndrome [39],
communicating hydrocephalus [40-43], meningioma
[44,45], cysts of the septum pellucidum [46] and medul-
loblastoma [44,47-55] (see the paragraph "Other
tumors"). Vermian dysgenesis has been noted in a mother
and a daughter [56,57]. Seizures have occasionally been
noted unassociated with brain tumors and possibly due to
focal neuronal heterotopia [58]. Mental retardation
occurs in about 5% of cases.
Skeletal system
Skeletal manifestations are also present in NBCCS [46].
The signs in the bones found on X-ray may be helpful in
making the diagnosis. The height (these patients can be
much taller than expected for their family), the shape of
the ribs, the shape of the bones in the vertebral column,
and the shape of the skull are principally affected [46,59].
Mean height is increased (183 cm in males, 174 cm in
females) and about 15% of patients are extremely tall [4].
An abnormal skull configuration (characterized by frontal
(25%), biparetial or temporal bossing, and large calvaria)Orphanet Journal of Rare Diseases 2008, 3:32 http://www.ojrd.com/content/3/1/32
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is frequent (70%) [11]. Relative macrocephaly with an
occipital frontal circumference above the 95th centile has
been reported in 50% of cases [6,59]. As a result of the
abnormal growth of the skull (> 60 cm in adults), about
70% of patients affected by NBCCS have eyes which
appear wider apart than usual. Other skeletal signs are
scoliosis (40%), and abnormalities such as bifid, wide,
fused, partially missing or underdeveloped ribs (30–60%)
[11]. Rib abnormalities may give rise to a prominent or
depressed sternum in about 30% – 40% of patients. Spina
bifida occulta of the cervical or thoracic vertebrae is found
in 60% of cases [60]. However, in a series studied by
Kimonis et al., the spina bifida occulta occurred in only
20% of patients [6]. Bifid wedges, fused vertebra and
Sprengel anomaly (elevation of the scapula with rotation
toward the spine with scoliosis) are observed in 10 to 40%
of patients. Extra digits on the hands or feet can occur. In
about 35% of individuals with Gorlin syndrome, an X-ray
of the hands will show small cysts in the bones of the fin-
gers. The numbers and site can be very variable. Bone cysts
can also occur in the long bones of the arms and legs, the
pelvis and the calvaria [61]; usually, these do not cause
problems, even if calvarial involvement may give the erro-
neous impression that medulloblastoma has spread to
bone [62]. Histologically, the flame-like lesions consist of
fibrous connective tissue, nerves, and blood vessels, i.e.,
they are hamartomas [4].
Ocular system
NBCCS patients may have various ocular problems that
occur with a frequency higher than that in the normal
population (20%). These include hypertelorism (70%),
exophthalmus, rotatory nystagmus, internal strabismus,
congenital cataracts, orbital cysts, coloboma of the iris,
choroid, and optic nerve, microphthalmia, and chalazi-
ons [5,11,21,63]. Most striking are small very transient
keratin-filled cysts (milia) found on the palpebral con-
junctivae in about 40% of cases [4]. This observation is a
personal one, reported by a parental support group in
Manchester, England [4]. The author asked the assembled
group if they had ever had one or more of these transient
cysts [4], and this exercise was repeated for the American
support group for NBCCS [4]. Due to the transient nature
of these cysts, most of the patients noted that they were
not significantly disturbed by their presence, but they had
been to ophthalmologists who confirmed the presence of
milia of the palpebral mucosa [4].
Genito-urinary system
Ovarian cysts and fibromas are present in 25–50% of
affected women [5] and are often bilateral (75%). Ovar-
ian calcifications are reported and may be mistaken for
calcified uterine fibroids or calcified uterine leiomyomas.
They do not seem to reduce fertility but may undergo tor-
sion (twist). Some cases of ovarian fibrosarcoma [64] and
primary ovarian leiomyosarcoma [65] have been
reported. Males may exhibit hypogonadotrophic hypogo-
nadism (5–10%), cryptorchidism, female pubic escutch-
eon, or gynecomastia. Other signs involving the kidneys
(5%) may be: horseshoe kidney, L-shaped kidney, unilat-
eral renal agenesis, renal cysts, or duplication of the renal
pelvis and ureter.
Mesenteric cysts
Single or multiple chylous or lymphatic mesenteric cysts
have been documented [4,66-68]. The cysts are thin-
walled and measure 2 to 14 cm in diameter, do not pro-
duce symptoms, and are often an occasional finding [21].
The content is chylous but may contain hemorrhagic tur-
bid fluid [4]. Microscopically, the wall is composed of
fibrous connective tissue and smooth muscle, and a layer
of lymphatic cells is often located beneath the endothelial
lining [4].
Cardiovascular system
Fibroma of the heart has been described [5,21,46,69-74].
The syndrome is present in 3–5% of all patients with a car-
diac fibroma [5,69]. The cardiac fibroma is discrete, well-
circumscribed, not encapsulated, firm, gray-white, 3 to 4
cm in diameter, and may, upon occasion, exhibit central
calcification [4]. The tumor is most often located in the
left anterior ventricular wall. If the tumor projects into the
chambers, hemodynamics is altered and/or impeded.
Conduction defects (i.e., arrhythmias) may also be
present due to involvement of the intraventricular septum
[75]. The tumors are composed of fibroblasts embedded
in a dense matrix of collagen and elastic fibers.
Other tumors
Tumors in patients with NBCCS include basal cell carci-
noma, medulloblastoma, fibroma and rhabdomyosar-
coma (RMS) [76-78]. RMSs are also present in 15% of
mice haplodeficient for PTCH1 [79]. Medulloblastoma is
frequent [44,47-55]; Herzberg and Wiskemann first
pointed out the association of NBCCS with medulloblas-
toma in 1963 [80]. The tumor characteristically presents
during the first two years of life, while in the general pop-
ulation occurrence peaks at 7 to 8 years of age. The inci-
dence of medulloblastoma in Evans' series was 1% to 2%
[5]. There is a sex predilection with a male-to-female ratio
of 3:1. Early onset medulloblastoma may be the present-
ing sign of NBCCS; thus, in children in which this tumor
is diagnosed, NBCCS should be suspected and a careful
examination for other signs of the syndrome should be
performed in order to rule it out [6]. There is some evi-
dence that medulloblastomas associated with NBCCS
have a better clinical outcome than those found in isola-
tion [47,81,82], with the possibility of spontaneous
recovery [82]. Radiation therapy for medulloblastoma canOrphanet Journal of Rare Diseases 2008, 3:32 http://www.ojrd.com/content/3/1/32
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induce invasive BCCs in the radiation field (i.e., from the
nape to base of the spine) [83].
Other brain tumors, such as astrocystoma, craniopharyngi-
oma, and oligodendroglioma, are infrequent, while meningi-
oma is slightly more common. These tumors may well be
secondary to radiation therapy.
In 1968, Schweisguth et al. reported fetal rhabdomyoma
[84]. This tumor has been described at various sites
[21,78,85-89]. Mature striated muscle within the tumor is
indicative for diagnosis.
There are several reports that support an increased inci-
dence of other neoplasms or hamartomas, such as leiomy-
omas of bowel and mesentery, leiomyosarcoma, adrenal
cystic lymphangioma, thyroid adenoma, lymphangiomy-
oma, melanoma, ameloblastoma, craniopharyngioma,
mesenchymoma, Hodgkin's lymphoma, non-Hodgkin's
lymphoma, seminoma, paratesticular pseudotumor,
schwannoma, pleiomorphic adenoma of parotid, ade-
noid cystic carcinoma of salivary gland, and adrenal
tumors [90-92].
Etiology
NBCCS is a hereditary condition caused by mutations in
the PTCH1 gene and is transmitted in an autosomal dom-
inant manner with high penetrance and variable expres-
sivity [93,94]. There is no sexual predilection. Individuals
with no known affected family members may comprise
up to 60% of all affected individuals [95].
The PTCH1 gene has recently been mapped to the long
arm of chromosome 9 (q22.3-q31) with no apparent het-
erogeneity [8,96]. Approximately 50% of NBCCS patients
have allelic losses including this site [97]. Data suggest
that the product of this gene acts as a tumor suppressor
[96,98,99]. Furthermore, the typical malformative pattern
of NBCCS suggests that the gene has a fundamental func-
tion in controlling growth and development of normal
tissues [100]. This gene was isolated in 1996 as the human
homolog of the Drosophila PTCH1 gene, simultaneously
in Australia and in the USA [101,102].
The PTCH1 gene in the fruit fly is important for body seg-
mentation. If the gene is faulty, abnormal segmentation
occurs. Several mutations of the PTCH1 gene have been
identified in patients with NBCCS [101-118], and, in
those with BCCs and medulloblastomas that are appar-
ently not hereditary [119,120].
The gene consists of 23 exons, which span 34 kb. It
encodes a transmembrane glycoprotein composed of
1447 amino acids, with 12 transmembrane domains and
two large hydrophilic extracellular loops where Sonic
Hedgehog (SHH) ligand binding occurs. If a mutation
occurs in PTCH1 and the second loop is not formed, SHH
cannot bind.
Thus, the PTCH1 gene product acts as membrane receptor
[121] for the SHH signal and represses transcription (in
certain cells) of genes encoding signaling proteins belong-
ing to the transforming growth factor (TGF)-beta and Wnt
families. The Hedgehog (Hh) family comprises several
regulation factors described in several species. SHH is a
true signaling switch used in differentiating subpopula-
tions of cells throughout the embryo; in fact, SHH pat-
terning is involved in several embryonal processes, such as
the formation of the ventral neural tube (basal plate,
motor columns), the limb bud, parts of the brain, hair fol-
licle development, and tooth development. PTCH1 in the
absence of its ligand, SHH, acts a cell-cycle regulator, nor-
mally inhibiting expression of downstream genes that
control cell fate, patterning, and growth [122]. In the case
of a C-terminal truncation caused by a mutation in
PTCH1, these genes are no longer repressed.
The molecular biology of cancers in NBCCS is similar to
that of retinoblastoma, the prototypical pediatric cancer
syndrome, which is characterized by mutations in a reces-
sive oncogene. Data from patients with retinoblastoma
support the Knudson two-hit hypothesis; this theory of
oncogenesis states that normal cells require two muta-
genic hits (two distinct episodes of DNA damage) to pro-
duce a cancer. Patients with retinoblastoma, NBCCS, and
other similar syndromes have a constitutional (germline)
defect in the DNA sequence in one of the two copies of a
tumor suppressor gene. A defect in one of the two copies
is insufficient to cause a cancer. If a second DNA injury or
if loss of the normal remaining allele occurs at the same
locus (the second hit), the cell may become malignant. In
NBCCS, various tumors and hamartomas (BCC, OKCs,
meningiomas, ovarian fibromas) exhibit loss of heterozy-
gosity [123,124], but other lesions do not, for example,
palmar pits [125]. Loss of heterozygosity at the PTCH1
locus has been observed in almost 90% of hereditary
BCCs. Various physical anomalies (bifid rib, macroceph-
aly) apparently need only one hit. An interesting aspect of
this syndrome is that some of the developmental defects
(e.g. jaw cysts) appear to have two genetic hits but without
developing into a true malignancy. In some patients, the
lining of these odontogenic keratocysts has lost the nor-
mal gene for NBCCS, while retaining the mutant allele.
Agaram et al. found that 70% of jaw cysts showed loss of
heterozygosity of one or more of the several common
tumor suppressor genes [126]. This finding may explain
the behavior of jaw cysts, which may be more similar to
low-grade neoplasms than congenital malformations.Orphanet Journal of Rare Diseases 2008, 3:32 http://www.ojrd.com/content/3/1/32
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Analysis of gene mutations in the syndrome has identified
deletions, insertions, splice site alterations, nonsense and
missense mutations, with no hot spots identified for
mutations. About 70% of germ-line PTCH1 mutations are
rearrangements. Over 80% of these mutations seem to
result in a truncation of the coded protein [115], which
suggests that developmental anomalies seen in NBCC
syndrome may be due to haplo-insufficiency [127];
recently, PTCH1 mutations have been reported as a result
of errors in the recombinational repair process [109].
In 2006 Lindström et al. analyzed 284 mutations and 48
single nucleotide polymorphisms (SNPs) located in the
PTCH1 gene, compiled from a PTCH1 mutation database
[110]. They found that the PTCH1 mutations were mainly
clustered into the two large extracellular loops of the cor-
responding protein and its large intracellular loop [110].
The SNPs appeared to be clustered around the sterol-sens-
ing domain and the second half of the protein [110].
NBCCS cases and each class of tumor analyzed revealed a
different distribution of the mutations in the various
PTCH1 domains [110]. Moreover, the types of mutations
were also unique for the different groups [110]. Finally,
the PTCH1 gene harbors mutational hot spot residues and
regions, including a slippage-sensitive sequence in the N-
terminus [110].
Several studies reported polymorphisms for the PTCH1
gene in North American [128], European [115,129], Chi-
nese [130], and Japanese [131] populations. Some of
these polymorphic variants (i.e., 1686C>T, 2199A>G,
3944T>C, IVS10-51G>C, IVS10-8T>C) occur with a high
frequency. A recent study has reported that certain haplo-
types of PTCH1 polymorphisms may mediate the suscep-
tibility to basal cell carcinomas [132]. Pedigrees with
multiple features of NBCCS were most likely to test posi-
tive for PTCH1 mutations [133]. Pedigrees with multiple
or early-onset basal cell carcinomas without other features
of the disease did not test positive for PTCH1 mutations
[133].
PTCH2, highly homologous to PTCH1, has been mapped
to chromosome 1p32.1-p32.3 [134]. PTCH2 comprises
22 coding exons and spans approximately 15 kb [134]. It
encodes a 1203 amino acid putative transmembrane pro-
tein that is highly homologous to the PTCH1 product.
Mutations have been found in one simplex case (i.e., a sin-
gle occurrence of the disease in a family) of medulloblas-
toma and one simplex case of BCC [134]. No PTCH2
mutations were found in 11 simplex cases of NBCCS or in
11 individuals with familial cases of NBCCS who did not
have identifiable PTCH1  mutations. In many cases,
medulloblastoma arising from perturbations of PTCH1
function leads to a concomitant up-regulation of the
highly similar gene PTCH2. Lee et al. investigated the role
of PTCH2 in tumor suppression by generating PTCH2-
deficient mice [135]. In striking contrast to PTCH1-/-
mice, PTCH2-/- animals were born alive and showed no
obvious defects and were not cancer prone [135]. How-
ever, loss of PTCH2 markedly affected tumor formation in
combination with PTCH1 haploinsufficiency. PTCH1+/-
PTCH2-/-  and  PTCH1+/-PTCH2+/-  animals showed a
higher incidence of tumors and a broader spectrum of
tumor types compared with PTCH1+/-  animals [135].
Therefore,  PTCH2  modulates tumorigenesis associated
with PTCH1 haploinsufficiency [135].
Diagnostic methods
Diagnosis of NBCCS can be made in the presence of two
major criteria or one major and two minor criteria [6]:
Major criteria
1. Multiple (>2) BCCs or one under 20 years
2. Odontogenic keratocysts of the jaws proven by histopa-
thology
3. Palmar or plantar pits (3 or more)
4. Bilamellar calcification of the falx cerebri
5. Bifid, fused or markedly splayed ribs
6. First degree relatives with NBCCS
Minor criteria
1. Macrocephaly determined after adjustment for height
2. Congenital malformation: cleft lip or palate, frontal
bossing, "coarse face", moderate of severe hypertelorism
3. Other skeletal abnormalities: sprengel deformity,
marked pectus deformity, marked syndactyly of the digits
4. Radiological abnormalities: bridging of the sella tur-
cica, vertebral anomalies such as hemivertebrae, fusion or
elongation of the vertebral bodies, modeling defects of
the hands and feet, or flame-shaped lucencies of the
hands or feet
5. Ovarian fibroma
6. Medulloblastoma.
The presence of the most frequent and/or specific features
of the syndrome make the diagnosis easier; however, diag-
nosis in a child with a 50% risk of having inherited the
condition may not be so easy because of the extreme var-
iation in expression, both within and between families.
Some children may have only rib anomalies, whilst othersOrphanet Journal of Rare Diseases 2008, 3:32 http://www.ojrd.com/content/3/1/32
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have the "typical face" without other signs. Gene tracking
and mutation analysis may be helpful for pre-sympto-
matic diagnosis.
For apparently isolated cases, detailed examination and X-
ray investigation of the relatives should be undertaken
before concluding that a child's condition is the result of
a new mutation. If an adult has no sign, no pertinent his-
tory and normal radiology, it is unlikely that he or she has
Gorlin syndrome. Direct mutation analysis of the gene
may be helpful. It is particularly helpful to follow a spe-
cific clinical protocol in the examination of these subjects
(Table 3).
In case of a family history of the disease, at birth or imme-
diately after, a detailed examination should look for the
presence of a large head, frontal and temporal bossing,
cleft palate [35], eye anomalies and bifid ribs [16,19], or
vertebral anomalies. In order to detect a deficit related to
a medulloblastoma, a neurological examination is recom-
mended every six months [5]. At 3 years, the frequency of
examinations could be reduced to once a year until 7 years
of age, after which a medulloblastoma is very unlikely.
A panoramic radiograph of the jaws once a year from the
age of 8 years onward is also suggested [18]. The appear-
ance of two or more recidivant OKCs, or an early OKC in
a young subject, is suggestive of NBCCS syndrome. An at
least annual examination of the skin from puberty is rec-
ommended but as a lesion may suddenly become aggres-
sive, the patient needs open access to the specialist taking
responsibility for treatment of the skin.
In children at risk, diagnosis can often be achieved by
radiographic means (calcification of falx, rib anomalies,
calcification of ovarian fibromas). Depending on the situ-
ation, imaging studies may include magnetic resonance
imaging (MRI) of the brain, echocardiography, abdomi-
nal ultrasonography, dental radiography, and skeletal sur-
vey. Kimonis et al. described the radiologic findings that
are most helpful in diagnosing NBCCS [46]. As patients
with NBCCS are especially sensitive to ionizing radiation,
the use of irradiation should be minimized when possi-
ble. Nevertheless, definitive presymptomatic diagnosis
can be achieved by molecular genetic linkage. Rarely,
babies can have fibromas in the heart: at least two cases
have presented before 3 months of age with fibromas
[71,136].
No specific laboratory studies are indicated; however, sev-
eral laboratories offer commercial testing for Gorlin syn-
drome and testing is certainly indicated in children with
desmoplastic medulloblastoma, where radiation is con-
templated. Patients with suspected Gorlin syndrome
should undergo biopsy with samples obtained from sev-
eral suspicious skin lesions. The histologic features of
BCCs in Gorlin syndrome are usually identical to those
observed in sporadic BCCs. Medulloblastomas in Gorlin
syndrome usually have the desmoplastic phenotype,
which has been linked, in some studies, with an improved
prognosis [47]. If an infratentorial mass is detected during
brain MRI, it should be sampled during biopsy as well.
The Chang staging system is used to stage medulloblast-
oma in Gorlin syndrome.
Differential diagnosis
Precise differential diagnosis needs exclusion of some rare
dermatological syndromes, such as Bazex syndrome
(characterized by basal-cell carcinoma associated with
hypotrichosis, hypohidrosis, milia and folliculare atro-
phodermia), trichoepithelioma papulosum multiplex
(named also epithelioma adenoides cysticum), or Torre's
syndrome (Muir-Torre's syndrome).
Genetic counseling
The syndrome is a hereditary condition, thus referral to a
geneticist for counseling is mandatory. NBCC syndrome is
caused when one copy of the PTCH1 gene pair contains a
fault; this means that every child of a person with the syn-
drome has a 1 in 2 (50:50) chance of inheriting the faulty
gene. The risk to family members is various, about 70–
80% of individuals diagnosed with NBCCS have an
affected parent and about 20–30% of probands have a de
novo mutation. The risk to a sib of a proband depends on
the genetic status of the parents: if a parent of the proband
is affected, the risk to the sibs is 50%; when the parents are
clinically unaffected, the risk to the sibs of a proband
appears to be low; if the disease-causing mutation cannot
Table 3: Diagnostic protocols in NBCCS.
Family history
 past medical and dental history
Clinical examinations
 oral
 skin
 central nervous system
 head circumference
 interpupillar distance
 eyes
 genito-urinary system
 cardio-vascular system
 respiratory system
 skeletal system
Genetic testing
X-ray
 chest
 A.P. and lateral skull
 Panoramic radiograph
 Cervical and thoracic spine – A.P. and lateral
 Hands (for pseudocysts)
 Pelvic (female)
Ovarian ultrasound (female) for ovarian fibroma
Echocardiogram (children) for cardiac fibromaOrphanet Journal of Rare Diseases 2008, 3:32 http://www.ojrd.com/content/3/1/32
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be detected in the DNA of the parent, the risk to sibs is
low, but greater than that of the general population
because of the possibility of somatic mosaicism or germ-
line mosaicism exists. The offspring of an individual with
mild NBCCS caused by somatic mosaicism may have a
risk of less than 50% of inheriting the disease-causing
mutation. The risk to other family members depends
upon the genetic status of the proband's parents; if a par-
ent is affected, his or her family members are at risk.
DNA tests, by looking directly at the mutation in the gene,
may confirm that the patient is affected by this syndrome.
In clinical situations suggesting genetic predisposition to
BCC, germline mutations of PTCH1  are not common
[107]. Genetic variants might contribute to the variation
in numbers of BCCs and jaw cysts observed in NBCCS
families [137].
It is recommended to involve families in regular screen-
ing. It may be possible to prove whether someone in a
family has inherited the condition or not by DNA tests,
either by tracking the chromosome 9 containing the faulty
gene, or by direct analysis of the mutation causing the dis-
ease in a particular family.
In some families, only one person appears to be affected.
This event is the result of two conditions: 1) the mother or
the father have the syndrome, but the effects are so mild
that it has never been diagnosed; 2) the fault in the PTCH1
gene has occurred for the first time in that family. It is a
"new mutation" [16]. If a family member has not inher-
ited the gene, the surveillance program is not necessary.
The definitive diagnostic test is to demonstrate a mutation
in the PTCH1  gene, although this is labor-intensive as
there are 24 exons. Recently Fujii et al. used newly
designed high-resolution oligonucleotide microarrays
with a median distance between the probes of 776 bp
(average probe interval 2,271 bp) to detect gene deletions
in NBCCS patients. This probe interval was chosen
because small submicroscopic genomic deletions and
duplications constitute up to 15% of all mutations under-
lying human monogenic diseases. Two out of three dele-
tions could not be detected by conventional
chromosomal analysis. A submicroscopic deletion as
small as 165 kb was detected affecting only PTCH1,
whereas the other two deletions were much larger (5 and
11 Mb) [138].
Antenatal diagnosis
Antenatal diagnosis may be useful to prevent complica-
tions. Ultrasound scans during pregnancy may be helpful
in detecting serious developmental malformations, even
if they are rare. Some fetuses with NBCCS have large heads
and so may need assistance in delivery either by forceps or
by Cesarian section. Very rarely, fibroma of the heart may
be detected. Prenatal diagnosis for pregnancies at
increased risk is possible by analysis of DNA extracted
from fetal cells obtained by amniocentesis (usually per-
formed at about 15–18 weeks of gestation) or by chori-
onic villus sampling (CVS) at about 10–12 weeks of
gestation. The disease-causing allele of an affected family
member must be identified or linkage established in the
family before prenatal testing can be performed. Requests
for prenatal testing for conditions such as NBCCS that do
not affect intellect, have variable expression and for which
some treatments are available, are not common.
Management including treatment
Patients affected by Gorlin syndrome must be treated by
several specialists. Keratocysts can be treated by surgical
removal. This requires exposure of the lesion by making
an osteotomy in the jawbone under local or general
anesthesia, finding the wall of the cyst and removing this
completely. Cysts that recur after such a treatment are
removed with a bone box including a layer of bone at the
margin of the cyst. This is intended to ablate any daughter
cysts; only in extreme cases it is necessary to remove an
entire section of the affected jawbone.
As regards BCC, only a small fraction of these tumors
become invasive and the very rare cases of death result
from spread to the brain or lung. Results from several epi-
demiologic studies have indicated that the risks of BCCs
show a strong positive correlation with exposure to UV
radiation. Thus, these patients need to avoid excess sun
exposure. They must use 100% UV protective sunglasses
as the skin surrounding the eyes (similar to that of the
nose/ears) is vulnerable to BCCs. Sunshine during the
mid-day hours should be avoided if possible. High factor
sunscreens (SPF30+) should be applied before going out-
side and re-applied every 2–3 hours, or more frequently,
if perspiring or swimming.
Radiotherapy should be avoided if possible [6,21].
Tumors on the scalp can be particularly aggressive and
need early intervention [5].
Management of superficial BCCs without follicular
involvement can be accomplished by total body applica-
tion of topical 0.1% tretinoin cream [16]. Patients should
be examined every 3 months, and lesions manifesting
growth must be excised [16]. More debatable is the use of
oral retinoids or combined oral etretinate and surgical
treatment [16]. Some authors indicated that doses of 0.5–
1.0 mg/kg/day cause regression of lesions of less than 1.0
cm and prevent new lesions [139]. Nevertheless, a study
of high-dose oral isotretinoin (mean daily dose: 3 mg/kg/
day) found that only 8% of BCCs underwent complete
clinical and histological regression, while all patientsOrphanet Journal of Rare Diseases 2008, 3:32 http://www.ojrd.com/content/3/1/32
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developed moderate-to-severe acute toxicity [140]. In
addition, oral etretinate should not be taken by women of
child-bearing age [16], a negative pregnancy test should
be obtained prior to therapy and adequate contraception
should be used by women during and for at least two
months after stopping isotretinoin therapy.
Recent studies indicated that imiquimod 5% cream
appears to be an effective treatment for nodular basal cell
carcinoma alone [141-145], or if combined with curettage
prior to its application [146]. In fact, 17 nodular BCCs on
15 patients were treated by curettage without electrodesic-
cation followed by once-daily application of imiquimod
5% cream, 5 times per week for 6 weeks; the area was
excised and examined histologically 6 weeks after cessa-
tion of imiquimod cream and all 17 lesions (100%)
showed no histological evidence of residual tumor on the
post-treatment excision [146].
Surgical excision is the typical approach for a patient with
BCC if the number of lesions is limited. Other treatments
that may be effective and more efficient than surgical exci-
sion in patients with multiple lesions include laser abla-
tion, photodynamic therapy, and topical chemotherapy
[147].
Electrodessication and curettage is a very common proce-
dure used as an alternative to topical chemotherapy in the
treatment of small BCCs located in low recurrence areas of
the body (neck, trunk, extremities) [148]. The area is first
numbed with a local anesthetic injection and then
scraped out from surrounding normal skin with a curette.
An electrosurgical needle is then used to desiccate (heat
and dry up) the remaining cancerous tissue. This is
repeated for a total of three or four times in succession in
order to achieve maximal cure rates. This form of treat-
ment is quick, efficient and cost effective, but it is of lim-
ited value for large lesions and cancers of the mid face due
to higher recurrence rates. Pain during treatment is mini-
mal and post-operatively the patient feels nuisance com-
parable to a small burn. The cosmetic result will appear as
a lighter hypopigmented flat spot that is of similar size as
the cancer was prior to treatment. The chance of a defini-
tive cure with this procedure is 92–93%. Another possibil-
ity is cryosurgery; it is quick, efficient and cost effective.
However, this method should be avoided when treating
lesions in high recurrence areas. The post-operative cos-
metic result, follow-up care, and healing time is very sim-
ilar to electrodessication and curettage. The overall chance
of a cure with this procedure is 92.5%. Cryosurgery, in a
few cases, was complicated by nerve damage and numb-
ness, but in general has no side effects, except for scarring.
Recently, laser vaporization with the carbon dioxide laser
has been used alone or combined with curettage in cases
of multiple/superficial tumors [149-151].
Surgical excision by scalpel allows removal of the cancer-
ous tissue plus surrounding normal skin, with minimal
discomfort during treatment and in the post-operative
period. The cosmetic result is good, but it depends on the
size and location of the tumor. The overall chance of a
cure with surgical excision may range from 94–98%. Long
term side effects include scarring, and rarely, nerve dam-
age. The scalpel excision gives the advantage of being able
to check the margins of the specimen microscopically by
a pathologist.
Another therapeutic possibility is photodynamic therapy
(PDT), a cancer treatment involving use of a photosensi-
tizing dye (given intravenously or topically) that preferen-
tially accumulates within malignant cells [16]. BCCs are
then treated with red light (usually produced by a laser)
that leads to dye activation and, definitively, to death of
these cells [16]. Scabs form over the basal cell carcinomas;
the scabs usually fall off by the end of the first month fol-
lowing PDT [16]. The management of patients with
NBCCS consists of regular visits (every 2–3 months) to a
dermatologist, especially during adolescence [16].
Recently, nodular BCCs resistant to multiple forms of
treatment in two patients with NBCCS were treated with
systemic porfimer sodium-based photodynamic therapy
with a good response to treatment on clinical evaluation
and on measurement by a 20-MHz high-resolution ultra-
sound [152].
Interferon has also been proposed in experimental studies
for the treatment of BCCs. This substance is injected
directly into the cancer three times each week, for three
weeks. Some reports have shown complete resolution of
treated tumors, but other studies demonstrated that this
treatment was less effective [153]. Side effects include
fever, chills, decreased white blood cell count, and pain at
the site of injection. This procedure needs to be investi-
gated further.
Patients with Gorlin syndrome can present with medul-
loblastoma, a malignant tumor of the posterior fossa [52].
Intensive multimodality therapy is typically required to
treat medulloblastoma. The best outcomes are obtained
in patients who are treated with aggressive resection,
chemotherapy, and radiation therapy. Radiotherapy for
medulloblastoma causes multiple BCCs in these patients
[154,155] or intracranial and sinonasal tumors [83,156-
158]; thus, post-operative radiotherapy should be used
judiciously. This is particularly important in patients with
the desmoplastic NBCCS subtype [47]. As a general rule,
if possible, patients should be treated without radiation
therapy or using a treatment field that only includes the
posterior fossa [159], with a skin-sparing nonconformal
technique [159]. In fact, the risk of multiple radiation-
induced BCC is decreased with this technique that allowsOrphanet Journal of Rare Diseases 2008, 3:32 http://www.ojrd.com/content/3/1/32
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the exposition of skin to ionizing radiation to be reduced.
On the contrary, this approach may increase the risk of
other well-established toxicities, such as ototoxicity and
irradiation of the temporal lobes.
Prognosis
The most common lesions accounting for NBCCS are usu-
ally not life-threatening. Medulloblastoma may be a
potential cause of early death, even if NBCCS patients
may have better outcome than patients with sporadic
medulloblastoma (as the desmoplastic subtype of medul-
loblastoma is associated with an improved survival com-
pared to the classic form of medulloblastoma). Therefore,
this could be one argument to limit therapy to young chil-
dren with Gorlin syndrome and desmoplastic medullob-
lastoma. Problems can derive from some techniques used
for the therapy of specific lesions: i.e. radiation therapy for
medulloblastoma that may cause multiple BCCs. For this
reason, nonstandard treatments should be considered in
children with Gorlin syndrome and medulloblastoma.
Chemoprevention may also be used to avoid skin lesions.
Vitamin A analogs, such as retinoids, including isotretin-
oin, may play an important role in preventing or slowing
the development of new BCCs [140,160-164].
Support groups
A list of groups that support patients, families, and clini-
cians caring for patients with NBCCS is supplied in Addi-
tional file 1.
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